Results 261 to 270 of about 19,767 (298)
Some of the next articles are maybe not open access.
Australian and New Zealand journal of obstetrics and gynaecology, 2020
In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility. A number of studies have established the safety of DA during pregnancy and the impact of pregnancy and lactation on remission of prolactinoma.
S. O'Sullivan +4 more
semanticscholar +1 more source
In women with prolactinoma medical treatment with dopamine agonists (DA) can restore fertility. A number of studies have established the safety of DA during pregnancy and the impact of pregnancy and lactation on remission of prolactinoma.
S. O'Sullivan +4 more
semanticscholar +1 more source
Pituitary, 2005
In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes.
Spada A., Mantovani G., Lania A.
openaire +3 more sources
In recent years the demonstration that human pituitary adenomas are monoclonal in origin provides further evidence that pituitary neoplasia arise from the replication of a single mutated cell in which growth advantage results from either activation of proto-oncogenes or inactivation of tumor suppressor genes.
Spada A., Mantovani G., Lania A.
openaire +3 more sources
MicroRNA-Mediated Drug Repurposing Unveiled Potential Candidate Drugs for Prolactinoma Treatment
Neuroendocrinology, 2021Introduction: Prolactinomas, also called lactotroph adenomas, are the most encountered type of hormone-secreting pituitary neuroendocrine tumors in the clinic.
B. Aydin +4 more
semanticscholar +1 more source
Clinical Endocrinology, 2020
To report the clinical presentation, management and outcomes of young patients with prolactinomas (
V. Arya +10 more
semanticscholar +1 more source
To report the clinical presentation, management and outcomes of young patients with prolactinomas (
V. Arya +10 more
semanticscholar +1 more source
Annual Review of Medicine, 1989
Prolactinomas are the most common of the hormone-secreting pituitary tumors and must be distinguished from nonsecreting tumors causing hyperprolactinemia by hypothalamic or stalk dysfunction. For both micro- and macroadenomas, dopamine agonists appear to be the treatment of choice, transsphenoidal surgery being reserved for nonresponders.
openaire +2 more sources
Prolactinomas are the most common of the hormone-secreting pituitary tumors and must be distinguished from nonsecreting tumors causing hyperprolactinemia by hypothalamic or stalk dysfunction. For both micro- and macroadenomas, dopamine agonists appear to be the treatment of choice, transsphenoidal surgery being reserved for nonresponders.
openaire +2 more sources
Endocrinology and Metabolism Clinics of North America
Prolactinomas are the most common type of pituitary adenomas and the most common cause of hyperprolactinemia. There are several pitfalls in the evaluation of hyperprolactinemia, which should be recognized as they affect management decisions. Medical therapy with dopamine agonists is the first-line treatment for prolactinomas. Transsphenoidal surgery is
Catherine D. Zhang +1 more
openaire +2 more sources
Prolactinomas are the most common type of pituitary adenomas and the most common cause of hyperprolactinemia. There are several pitfalls in the evaluation of hyperprolactinemia, which should be recognized as they affect management decisions. Medical therapy with dopamine agonists is the first-line treatment for prolactinomas. Transsphenoidal surgery is
Catherine D. Zhang +1 more
openaire +2 more sources
Archives of Internal Medicine, 1979
In the past ten years, hyperprolactinemia has been implicated as a possible cause of several common medical problems. One of the first recognized was the so-called amenorrhea-galactorrhea syndrome. Subsequently it was learned that not all patients with elevated prolactin levels have galactorrhea 1 (only about 20% of hyperprolactinemic women and even ...
openaire +2 more sources
In the past ten years, hyperprolactinemia has been implicated as a possible cause of several common medical problems. One of the first recognized was the so-called amenorrhea-galactorrhea syndrome. Subsequently it was learned that not all patients with elevated prolactin levels have galactorrhea 1 (only about 20% of hyperprolactinemic women and even ...
openaire +2 more sources
MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
Endocrine Practice, 2019Objective: To describe outcomes of patients with giant prolactinoma (≥4 cm) and identify predictors of therapeutic response. Methods: In this retrospective study, complete biochemical and structural response were defined as prolactin (PRL) ≤25 ng/mL and ...
Oksana Hamidi +11 more
semanticscholar +1 more source
CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma
Journal of Endocrinological Investigation, 2023N. Wu +8 more
semanticscholar +1 more source
Ossified Prolactinoma: Case Report
Neurosurgery, 1987Abstract The authors report a case of ossified prolactinoma that was identified as a calcified nodule on the roentgenograms. Histologically, the ossified tissues were diffuse, and the osteoid was mineralized in various degress, subsequently forming bones. Adenoma cells were sparse among the ossified tissues.
K, Mukada +5 more
openaire +2 more sources